Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun Pharma Acquires Rights to Next-Gen Botox-type Drug in $260 Million Deal

publication date: Dec 5, 2018

Shanghai Fosun Pharma in-licensed rights to a Revance (NSDQ: RVNC) neuromodulator for aesthetic and therapeutic use in an agreement potentially worth $260 million. Fosun will pay $30 million upfront and up to $230 million in milestones, plus royalties. The first neuromodulator with long-acting duration, DaxibotulinumtoxinA (RT002) is also the first Botox-type product formulated without human blood-derived products or manufactured using animal-derived proteins. More details....

Stock Symbol: (SHA: 600196; HK: 02196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.